posted 19th November 2025
The year to 31 March 2025 saw much even more MDT engagement, structural changes and the firming up of discussions that have been taking shape over the years, particularly mortality discussion. New trends and pathways were identified and constructed with the onset of gene therapy for Transfusion-dependent Thalassaemia and Sickle Cell Disorder. This was an exciting challenging and worthwhile year in the NHP network. Read more in the linked file below.
